Candida urinary tract infection: Pathogenesis

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 6, 2011, Pages

  Fisher, John F ^a   Kavanagh, Kevin ^b,d   Sobel, Jack D ^b   Kauffman, Carol A ^c   Newman, Cheryl A ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HEMOLYSIN; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPASE; VIRULENCE FACTOR;

ARTICLE; BIOFILM; CANDIDA; CANDIDEMIA; CANDIDIASIS; DIABETES MELLITUS; ENTEROBACTERIACEAE; FUNGAL COLONIZATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RISK FACTOR; URINARY TRACT INFECTION;

ANIMALS; CANDIDA; CANDIDIASIS; CARRIER STATE; CATHETERS; DISEASE PROGRESSION; ENTEROBACTERIACEAE; FEMALE; HUMANS; KIDNEY; MALE; MICE; RABBITS; URINARY TRACT INFECTIONS; VIRULENCE FACTORS;

EID: 79955386743     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir110     Document Type: Article

References (142)

1. Drasar BS, Shiner M, McLeod GM. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology 1969; 56:71-9.
2. Gorbach SL, Nahas L, Lerner PJ, Weinstein L. Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology 1967; 53:845-55.
3. Tashjian JM, Coulam CB, Washington JAI. Vaginal flora in asymptomatic women. Mayo Clin Proc 1976; 51:557-61.
4. Nassoura Z, Ivatury RR, Simon RJ, Jabbour M, Stahl WM. Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. J Trauma 1993; 35:290-5. (Pubitemid 23249778)
5. Louria DB, Brayton RG, Finkel G. Studies on the pathogenesis of experimental Candida albicans infections in mice. Sabouraudia 1963; 2:217-83.
6. Hurley R, Winner HI. Experimental renal moniliasis in the mouse. J Path Bacteriol 1963; 86:75-83.
7. Albers DD. Monilia infection of the kidney. J Urol 1953; 69:32-8.
8. Tomashefski JF, Abramowsky CR. Candida-associated papillary necrosis. Amer J Clin Pathol 1981; 75:190-4.
9. MacCallum D, Odds F. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 2005; 48:151-61. (Pubitemid 40592846)
10. Spellberg B, Johnston D, Phan QT, et al. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 2003; 71:5756-64. (Pubitemid 37205629)
11. Odds FC. Candidosis of the urinary tract. In: Odds FC, ed. Candida and candidosis: a review and bibliography. London: Balliere Tindall, 1988: 169-74.
12. Louria DB, Stiff DP, Bennett B. Disseminated moniliasis in the adult. Medicine (Baltimore) 1962; 41:307-37.
13. Spellberg B, Ibrahim AS, Edwards JE Jr., Filler SG. Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 2005; 192:336-43. (Pubitemid 40993405)
14. Fisher JF, Mayhall CG, Duma RJ, Shadomy S, Shadomy HJ, Watlington C. Fungus balls of the urinary tract. South Med J 1979; 72:1281-4.
15. Ryley JF, Ryley NG. Candida albicans-do mycelia matter? J Med Vet Mycol 1990; 28:225-39.
16. MacCallum D, Castillo L, Brown A, Gow N, Odds F. Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS One 2009; 4:e6420.
17. Heinsbroek SEM, Brown GD, Gordon S. Dectin-1 escape by fungal dimorphism. Trends Immunol 2005; 26:352-4. (Pubitemid 40835839)
18. Luyckx VA, Cairo LV, Compston CA, Phan WL, Mueller TF. The oncostatin M pathway plays a major role in the renal acute phase response. Am J Physiol-Renal Physiol 2009; 296:F875-83.
19. Brieland J, Essig D, Jackson C, et al. Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun 2001; 69:5046-55. (Pubitemid 32674490)
20. Romani L, Puccetti P, Mencacci A, et al. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol 1994; 152:3514-21. (Pubitemid 24098048)
21. Fidel PL, Vasquez JA, Sobel JD. Candida glabrata. Review of epidemiology, pathogenesis, and clinical disease with comparison to Candida albicans. Clin Microbiol Rev 1999.
22. Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis 1999; 34:213-20. (Pubitemid 29287215)
23. Odds FC, Gow NA, Brown AJ. Fungal virulence studies come of age. Genome Biol 2001; 2:1009.1-4.
24. Haynes K. Virulence in Candida species. Trends Microbiol 2001; 9:591-5.
25. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190:624-31. (Pubitemid 38982105)
26. Soll DR, Galask R, Schmid J, Hanna C, Mac K, Morrow B. Genetic dissimilarity of commensal strains of Candida spp. carried in different anatomical locations of the same healthy women. J Clin Microbiol 1991; 9:1702-10.
27. Schmid J, Rotman M, Reed B, Pierson CL, Soll DR. Genetic similarity of Candida albicans strains from vaginitis patients and their partners. J Clin Micrbiol 1993; 31:39-46. (Pubitemid 23006575)
28. Svanborg-Eden C, Eriksson B, Hanson LA. Adhesion of Escherichia coli to human uroepithelial cells in vitro. Infect Immun 1977; 18:767-74. (Pubitemid 8247696)
29. Kallenius G, Mollby R, Svenson SB, et al. Occurrence of P-fimbriated Escherichia coli in urinary tract infections. Lancet 1981; 2:1369-72. (Pubitemid 12239441)
30. Pendrak ML, Klotz SA. Adherence of Candida albicans to host cells. FEMS Microbiol Letts 1995; 129:103-14.
31. Fisher JF. Candiduria: when and how to treat it. Curr Infect Dis Rep 2000; 2:523-30.
32. Cotter G, Kavanagh K. Adherence mechanisms of Candida albicans. Br J Biomed Sci 2000; 57:241-9.
33. Schmid J, Hunter P, White G, Nand A, Cannon R. Physiological traits associated with success of Candida albicans strains as commensal colonisers and pathogens. J Clin Microbiol 1995; 33:2920-26.
34. Ruiz-Herrera J, Elorza MV, Valentin E, Sentandreu R. Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS Yeast Res 2005; 6:14-29.
35. Hoyer LL, Green CB, Oh SH, Zhao X. Discovering the secrets of Candida albicans agglutinin-like sequence (ALS) gene family-a sticky pursuit. Med Mycol 2008; 46:1-15. (Pubitemid 351298235)
36. Li F, Palecek SP. EAP1, a Candida albicans gene involved in binding human epithelial cells. Eukaryot Cell 2003; 2:1266-73. (Pubitemid 38047235)
37. de Groot PWJ, Kraneveld E, Yin QY, et al. The cell wall of the human pathogen Candida glabrata: differential incorporation of novel adhesin-like wall proteins. Eukaryot Cell 2008; 7:1951-64.
38. Bouchara JP, Tronchin G, Annaix Y, Robert R, Senet JM. Laminin receptors on Candida albicans germ tubes. Infect Immun 1990; 58:48-54. (Pubitemid 20064863)
39. Vardar-Unlu G. Identification of fibronectin adhesins on Candida albicans. Tr J Med Sci 1998; 28:475-80.
40. Alonso R, Llopis I, Flores C, Murgui A, Timoneda J. Different adhesins for type IV collagen on Candida albicans: identification of a lectin-like adhesin recognizing the 7S(IV) domain. Microbiology 2001; 147:1971-81. (Pubitemid 32684939)
41. Hazen KC. Participation of yeast cell surface hydrophobicity in adherence of Candidal albicans to human epithelial cells. Infect Immun 1989; 57:1894-900. (Pubitemid 19186859)
42. Hazen K, Brawner D, Riesselman M, Jutila M, Cutler J. Differential adherence of hydrophobic and hydrophilic Candida albicans yeast cells to mouse tissues. Infect Immun 1991; 59:907-12.
43. Hazen K, Hazen B. Hydrophobic surface protein masking by the opportunistic fungal pathogen Candida albicans. Infect Immun 1992; 60:1499-508.
44. Masuoka J, Hazen KC. Cell wall protein mannosylation determines Candida albicans cell surface hydrophobicity. Microbiology 1997; 143:3015-21. (Pubitemid 27437919)
45. Masuoka J, Hazen BW. Cell wall mannan and cell surface hydrophobicity in Candida albicans serotype A and B strains. Infect Immun 2004; 72:6230-6. (Pubitemid 39425399)
46. Singleton DR, Masuoka J, Hazen KC. Surface hydrophobicity changes of two Candida albicans serotype B mn4 delta mutants. Eukaryot Cell 2005; 4:639-48. (Pubitemid 40600418)
47. Centeno A, Davis CP, Cohen MS, Warren MM. Modulation of Candida albicans attachment to human epithelial cells by bacteria and carbohydrates. Infect Immun 1983; 39:1354-60. (Pubitemid 13159983)
48. Lyman CA, Navarro E, Garrett KF, Roberts DD, Pizzo PA, Walsh TJ. Adherence of Candida albicans to bladder mucosa: development and application of a tissue explant assay. Mycoses 1999; 42:255-9. (Pubitemid 29330594)
49. Lundstrom T, Sobel JD. Nosocomial candiduria: a review. Clin Infect Dis 2001; 32:1602-7. (Pubitemid 32458728)
50. Domergue R, Castano I, De Las Penas A, et al. Nicotinic acid limitation regulates silencing of Candida adhesins during UTI. Science 2005; 308:866-70. (Pubitemid 40629269)
51. Silva S, Negri M, Henriquez M, Oliveira R, Williams D, Azeredo J. Silicone colonisation by non-Candida albicans Candida species in the presence of urine. J Med Microbiol 2010; 59: DOI: 10.1099/ jmm.0.017517-0.
52. Mackenzie DW. Studies on the morphogenesis of Candida albicans. II. Growth in organ extract. Sabouraudia 1965; 4:126-30.
53. Csank C, Haynes K. Candida glabrata displays pseudohyphal growth. FEMS Microbiol Letts 2000; 189:115-20. (Pubitemid 30456257)
54. Lachke SA, Joly S, Daniels K, Soll DR. Phenotypic switiching and filamentation in Candida glabrata. Microbiology 2002; 148:2661-74.
55. Kauffman C, Tan J. Torulopsis glabrata renal infection. Amer J Med 1974; 57:217-24.
56. Frye KR, Donovan JM, Drach GW. Torulopsis glabrata urinary infections: a review. J Urol 1988; 139:1245-9.
57. Wise GJ. Ureteral stent in the management of fungal pyonephrosis due to Torulopsis glabrata. Urology 1984; 24:128-9. (Pubitemid 15199494)
58. Graybill J, Galgiani J, Jorgensen J, Strandberg D. Ketoconazole therapy for fungal urinary tract infections. J Urol 1983; 129:68-70. (Pubitemid 13148053)
59. Corbella X, Carratala J, Castells M, Berlanga B. Fluconazole treatment in Torulopsis glabrata upper urinary tract infection causing ureteral obstruction. J Urol 1992; 147:1116-7.
60. Romani L, Bistoni F, Puccetti P. Adaptation of Candida albicans to the host environment: the role of morphogenesis in virulence and survival in mammalian hosts. Curr Opin Microbiol 2003; 6:338-43. (Pubitemid 37075349)
61. Kretschmar M, Hube B, Bertsch T, et al. Germ tube production and proteinase activity contributes to virulence of Candida albicans in murine peritonitis. Infect Immun 1999; 67:6637-42.
62. Abaitua F, Rementeria A, San Millan R, et al. In vitro survival and germination of Candida albicans in the presence of nitrogen compounds. Microbiol 1999; 145:1641-7. (Pubitemid 29352008)
63. Hazen K, Cutler J. Isolation and purification of morphogenic autoregulatory substance produced by Candida albicans. J Biochem 1983; 94:777-83.
64. Alem MA, Oteef MD, Flowers TH, Douglas LJ. Production of tyrosol by Candida albicans biofilms and its role in quorum sensing and biofilm development. Eukaryot Cell 2006; 5:1770-9. (Pubitemid 44622603)
65. Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001; 67:2982-92. (Pubitemid 33644762)
66. Dhammika H, Navarathna L, Nickerson K, Duhamel G, Jerrels T, Petro T. Exogenous farnesol interferes with the normal progression of cytokine expression during candidiasis in a mouse model. Infect Immun 2007; 75:4006-11. (Pubitemid 47206299)
67. Dhammika HM, Navarathna LP, Hornby JM, et al. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun 2007; 75:1609-18. (Pubitemid 46559424)
68. Brand A, Vacharaska A, Bendel C, et al. An internal polarity landmark is important for externally induced hyphal behaviors in Candida albicans. Eukaryot Cell 2008; 7:712-20. (Pubitemid 351959905)
69. Brand A, Shanks S, Duncan VMS, Yang M, Mackenzie K, Gow NAR. Hyphal orientation of Candida albicans is regulated by a calciumdependent mechanism. Curr Biol 2007; 20:347-52. (Pubitemid 46241887)
70. Brand A, Lee K, Veses V, Gow NAR. Calcium homeostasis is required for contact-dependent helical and sinusoidal tip growth in Candida albicans hyphae. Mol Microbiol 2009; 71:1155-64.
71. Sherwood-Higham J, Zhu WY, Devine CA, Gooday GW, Gow NAR, Gregory DW. Helical growth of hyphae of Candida albicans. J Med Vet Mycol 1994; 32:437-45.
72. Gow NAR, Perera THS, Sherwood-Higham J, Gooday GW, Gregory DW, Marshall D. Investigation of touch sensitive responses by hyphae of the human pathogenic fungus Candida albicans. Scanning Microsc 1994; 8:705-10.
73. Odds FC. Candida albicans proteinase as a virulence factor in the pathogenesis of Candida infections. Zbl Bakteriol [A] 1985; 260:539-42.
74. Soll DR. Molecular biology of switching in Candida. In: Calderone RA, Cihlar RL eds. Fungal Pathogenesis. Washington, DC: Marcel Dekker, Inc., 2002: 161-82.
75. Slutsky BM, Staebell M, Anderson J, Risen L, Pfaller M, Soll DR. White-opaque transition: a second high-frequency switching system in Candida albicans. J Bacteriol 1987; 169:189-97. (Pubitemid 17228707)
76. Soll DR. High frequency switching in Candida albicans. Clin Microbiol Rev 1992; 5:183-203.
77. Morrow B, Anderson J, Wilson E, Soll DR. Bidirectional stimulation of the white-opaque transition of Candida albicans by ultraviolet radiation. J Gen Microbiol 1989; 135:1201-8. (Pubitemid 19135402)
78. Bedell GW, Soll DR. Effects of low concentrations of zinc on the growth and dimorphism of Candida albicans: evidence for zincresistant and-sensitive pathways for mycelium formation. Infect Immun 1979; 26:348-54. (Pubitemid 10245649)
79. Lohse MB, Johnson AD. White-opaque switching in Candida albicans. Curr Opin Microbiol 2009; 12:650-4.
80. Vargas KG, Messer MA, Pfaller MA, Lockhart SR, Stapleton JT, Soll DR. Elevated switching and drug resistance of Candida from HIV-positive individuals prior to thrush. J Clin Micrbiol 2000; 38:3595-607.
81. Vargas K, Wertz PW, Drake D, Morrow B, Soll DR. Differences in adhesion of Candida albicans 3153A cells exhibiting switch phenotypes of buccal epithelium and stratum corneum. Infect Immun 1994; 62:1328-35. (Pubitemid 24110827)
82. Kvaal C, Srikantha T, Daniels K, McCoy J, Soll DR. Misexpression of the opaque pahse-specific gene PEPI (SAPI) in the white phase of Candida albicans enhances growth in serum and virulence in a cutaneous model. Infect Immun 1999; 67:6652-62.
83. Anderson J, Mihalik R, Soll DR. Ultrastructure and antigenicity of the unique cell wall ''pimple'' of the Candida opaque phenotype. J Bacteriol 1990; 172:224-35. (Pubitemid 20016836)
84. Calderone R, Cihlar R, Lee D, Hoberg K, Scheld W. Yeast adhesion in the pathogenesis of endocarditis due to Candida albicans: studies with adherence-negative mutants. J Infect Dis 1985; 152:710-15. (Pubitemid 16215946)
85. McCourtie J, Douglas LJ. Relationship between cell surface composition of Candida albicans and adherence to acrylic after growth on different carbon source. Infect Immun 1981; 32:1234-41. (Pubitemid 11109834)
86. McCourtie J, Douglas L. Relationship between cell surface composition, adherence, and virulence of Candida albicans. Infect Immun 1984; 45:6-12. (Pubitemid 14078908)
87. Anderson JM, Mihalik R, Soll DR. Ultrastructure and antigenicity of the unique cell and pimple of the Candida opaque phenotype. J Bacteriol 1990; 172:224-35. (Pubitemid 20016836)
88. Anderson JM, Soll DR. Unique phenotype of opaque cells in the white-opaque transition of Candida albicans. J Bacteriol 1987: 5579-88. (Pubitemid 18017848)
89. Kolotila MP, Diamond RD. Effects of neutrophils and in vitro oxidants on survival and phenotypic switching of Candida albicans WO-1. Infect Immun 1990; 58:1174-9. (Pubitemid 20151774)
90. Jones S. Increased phenotypic switching in strains of Candida albicans associated with invasive infections. J Clin Microbiol 1994; 32:2869-70. (Pubitemid 24319140)
91. Soll DR. High-frequency switching in Candida albicans and its relation to vaginal candidiasis. Am J Obstet Gynecol 1988; 158:997-1001.
92. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961-71. (Pubitemid 46874580)
93. Borst A, Fluit AC. High levels of hydrolytic enzymes secreted by Candida albicans isolates involved in respiratory infections. J Med Microbiol 2003; 52:971-4. (Pubitemid 38648136)
94. Schaller M, Schackert C, Korting HC, Januschke E, Hube B. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infections of human epidermis. J Invest Dermatol 2000; 114:712-14.
95. Goldman RC, Frost DJ, Capobianco JO, Kadam S, Rasmussen RR. Antifungal drug targets: Candida-secreted aspartyl protease and fungal wall beta-glucan synthesis. Infect Agents Dis 1995; 4:228-47. (Pubitemid 26002077)
96. Zaugg C, Borg-Von Zepelin M, Reichard U, Sanglard D, Monod M. Secreted aspartyl proteinase family of Candida tropicalis. Infect Immun 2001; 69:405-12. (Pubitemid 32038339)
97. Monod M, Togni G, Hube B, Sanglard D. Multiplicity of genes secreted aspartic proteinases in Candida species. Mol Microbiol 1994; 13:357-68. (Pubitemid 24225506)
98. Gilfillan GD, Sullivan DJ, Haynes K, Parkinson T, Coleman DC, Gow NA. Candida dubliniensis: phylogeny and putative virulence factors. Microbiol 1998; 144:829-38. (Pubitemid 28187909)
99. Kaur R, Domergue R, Zupancic M, Cormack BP. A yeast by any other name: Candida glabrata and its interaction with the host. Curr Opin Microbiol 2005; 8:378-84. (Pubitemid 41021896)
100. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67:400-28. (Pubitemid 37122527)
101. Staib P, Kretschmar M, Nichterlein T, et al. Host-induced, stage specific virulence gene activation in Candida albicans during infection. Mol Microbiol 1999; 32:533-46. (Pubitemid 29233898)
102. Hube B, Turver CJ, Odds FC, et al. Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect Immun 1997; 65:3529-38. (Pubitemid 27398104)
103. Fallon K, Bausch K, Noonan J, Huguenel E, Tamburini P. Role of aspartic proteases in disseminated infection in mice. Infect Immun 1997; 55:551-6. (Pubitemid 27053224)
104. Mukherjee P, Ghannoum M. Secretory proteins in fungal virulence. In: Calderone RA, Cihlar RL eds. Fungal Pathogenesis. New York: Marcel Dekker Inc., 2002: 51-79.
105. De Bernardis F, Mondello F, San Millan R, Ponton J, Cassone A. Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol 1999; 37:3481-6. (Pubitemid 29491078)
106. Kohler GA, Brenot A, Haas-Stapleton E, Agabian N, Deva R, Nigam S. Phospholipase A2 and phospholipase B activities in fungi. Biochim Biophys Acta 2006; 1761:1391-9.
107. Ibrahim AS, Mirbod F, Filler SG, et al. Evidence implicating phospholipase as a virulence factor in Candida albicans. Infect Immun 1995; 63:1993-8.
108. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenicity. Clin Microbiol Rev 2000; 13:122-43. (Pubitemid 30039346)
109. Leidich SD, Ibrahim AS, Fu Y, et al. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem 1998; 273:26078-86. (Pubitemid 28475842)
110. Pugh D, Cawson RA. The cytochemical localization of phospho-lipase in Candida albicans infecting the chick chorioallantoic membrane. Sabouraudia 1977; 15:29-35. (Pubitemid 8060617)
111. Vitullo J, Leidich SD, Jessup CJ, Ghannoum MA. In vivo expression of phospholipase B is associated with invasive infection of Candida albicans [abstract 98]. Proc Am Soc MIcrobiol. May 17-21; 1998: 98-259.
112. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 1982; 20:7-14. (Pubitemid 12161206)
113. Basu S, Gugnani HC, Joshi S, Gupta N. Distribution of Candida species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of Candida albicans isolates. Rev Iberoam Micol 2003; 20:137-40. (Pubitemid 38724619)
114. da Silva EH, daSilva-Ruiz L, Matsumoto FE, et al. Candiduria in a public hospital of Sao Paulo (1999-2004): characteristics of the yeast isolates. Rev Inst Med trop Sao Paulo 2007; 49:349-53.
115. Manns JM, Mosser DM, Buckley HR. Production of hemolytic factor in Candida albicans. Infect Immun 1994; 62:5154-6. (Pubitemid 24332827)
116. Otto BR, Verweij-van Vught AM, MacLaren DM. Transferrins and heme compounds as iron sources for pathogenic bacteria. Crit Rev Microbiol 1992; 18:217-33.
117. Luo G, Samaranayake L, Yau J. Candida species exhibit differential in vitro haemolytic activities. J Clin Microbiol 2001; 39:2971-4. (Pubitemid 32744023)
118. Linares CEB, de Loreto ES, Silveira CP, et al. Enzymatic and hemolytic activities of Candida dubliniensis strains. Rev Inst Med trop Sao Paulo 2007; 49.
119. Malcok HK, Aktas E, Ayyildiz A, Yigit N, Yazgi H. Hemolytic activities of the Candida species in liquid medium. Euras J Med 2009; 41:95-8.
120. Luo G, Samaranayake LP, Cheung BPK, Tang G. Reverse transcriptase polymerase chain reactin (RT-PCR) detection of HLP gene expression in Candida glabrata and its possible role in in vitro haemolysin production. APMIS 2004; 112:283-90. (Pubitemid 39005911)
121. Seker E. Identification of Candida species isolated from bovine mastitic milk and their role in vitro hemolytic activity in western Turkey. Mycopathologia 2010; 169:303-8.
122. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003; 11:30-6. (Pubitemid 36084353)
123. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994; 62:915-21. (Pubitemid 24065575)
124. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46:1773-80. (Pubitemid 34535196)
125. Odds FC. Pathogenesis of Candida infections. J Amer Acad Dermatol 1994; 31:S2-S5. (Pubitemid 24280337)
126. Odds FC, Van Nuffel L, Gow NAR. Survival in experimental Candida albicans infections depends on inoculum growth conditions as well as animal host. Microbiology 2000; 146:1881-9. (Pubitemid 30639263)
127. Voss A, Meis JF, Hoogkamp-Korstanje JA. Fluconazole in the management of fungal urinary tract infections. Infection 1994; 4:247-51. (Pubitemid 24255175)
128. Ibrahim AS, Filler SG, Sanglard D, Edwards JE Jr., Hube B. Secreted aspartyl proteinases and interaction of Candida albicans with human endothelial cells. Infect Immun 1998; 66:3003-5. (Pubitemid 28261818)
129. Filler S, Swerdloff J, Hobbs C, Luckett P. Penetration and damage of endothelial cells by Candida albicans. Infect Immun 1995; 63:976-83.
130. Iwamoto N, Yoshioka T, Nitta K, Ito K. Glomerular endothelial injury associated with free radical production induced by a fungal cell wall component, 1-3 beta-D glucan. Life Sci 1998; 62:247-55. (Pubitemid 28057230)
131. Navarro EE, Almario JS, King C, Bacher J. Detection of Candida casts in experimental renal candidiasis: implications for the diagnosis and pathogenesis of upper tract infections. J Med Vet Mycol 1994; 32:415-26.
132. Wagner D, Sander A, Bertz H, Finke J, Kern WV. Breakthrough invasive infection due to Dabaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection 2005; 33:397-400. (Pubitemid 41552023)
133. Lockhart SR, Messer SA, Pfaller M, Diekema DJ. Lodderomyces elongisporis masquerading as Candida parapsilosis as a cause of bloodstream infections. J Clin Micrbiol 2008; 46:374-6.
134. Salim R, van Gelderen de Komaid A. In vivo determination of phagocytic indices and candidacidal activities of Candida species by rat peritoneal macrophages. Mycopathologia 1986; 95:17-23.
135. Wise G. Genitourinary candidal infection. AUA Update Series 1989 1989; 8:193-200.
136. Sobel JD. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl JMed 1986; 315:1455-8. (Pubitemid 17051706)
137. Gip L, Molin L. On the inhibitory activity of human prostatic fluid on Candida albicans. Mykosen 1978; 13:61-3.
138. Parkash C, Chugh TD, Gupta SP, Thanik KD. Candida infection of the urinary tract-an experimental study. J Assoc Physicians India 1970; 18:497-502.
139. Levison ME, Pitsakis PG. Susceptibility to experimental Candida albicans urinary tract infections in the rat. J Infect Dis 1987; 155:841-6. (Pubitemid 17062816)
140. Nair RG, Samaranayake LP. The effect of commensal bacteria on candidal adhesion to human buccal epithelial cells in vitro. J Med Microbiol 1996; 45:179-85. (Pubitemid 26294871)
141. De Bernardis F, Muhlschlegel FA, Cassone A, Fonzi WA. The pH of the host niche controls gene expression in and virulence of Candida albicans. Infect Immun 1998; 66:3317-25. (Pubitemid 28303132)
142. Gallis HA, Sobel JD. Candiduria. In: Mandell GL ed. Atlas of Infectious Diseases, 9th ed. 1997. 5.3.